biostudies-literaturePinal-Fernandez INational Institute of Arthritis and Musculoskeletal and Skin DiseasesNational Institute of Environmental Health SciencesIntramural NIH HHSNIEHS NIH HHSMyositis AssociationNIAMS NIH HHSThe Myositis Association358-364https://www.ebi.ac.uk/biostudies/studies/S-EPMC8792092biostudies-literatureUnknown74(2)<h4>Objective</h4>To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.<h4>Methods</h4>In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared.<h4>Results</h4>Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoaArthritis & rheumatology (Hoboken, N.J.)Anti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.PMC8792092ZIA AR041203Siegel DAlbayda JRosenkranz MNanda KLloyd TEDeGuzman MMEdelheit BSBarillas-Arias LHuber ABohnsack JFSabbagh SGeorge SWCartwright VVogelgesang SABallinger SEbernardt BACasciola-Rosen LChildhood Myositis Heterogeneity Collaborative Study GroupRay LIHiggins GCKingsbury DJDare JBaucells ARennebohm RMWeiser PTiniakou EKimura YCawkwell GDPerson DACuriel RMiller FWArabshahi BShenoi SZhao YInman CHenrickson MEl-Hallak MCasal-Dominguez MPaik JPinal-Fernandez IChristopher-Stine LHoftman AShaham BStoll MWargula JCSchiffenbauer ARonis TZeft AJansen ASmukler AEade KKnibbe WPSundel RCarrasco RMilojevic DImundo LSelva-O'Callaghan ASule SHWahezi DJung LSchmeling HSoep JGoldmuntz EATarvin SHong SModica RHobday PPerez MDRothman DLang BAGil-Vila AMitchell SRDerfoul AMartinez-Carretero MAMammen ALLeffler MTesher MZemel LSO'Hanlon TJarvis JWhite PHGraham BGottlieb BBingham CAKahn PPak KKatona IMMyers LPachman LMBalboni IHannan WMadson KLMamyrova GPasso MHBecker MRivas-Chacon RFLerman MSherry DWeiss PNativ SVolochayev RPlotz BOlson JCRider LGDanoff SKFinkel THPunaro MGLindsley CBfalseAnti-Cortactin Autoantibodies Are Associated With Key Clinical Features in Adult Myositis But Are Rarely Present in Juvenile Myositis.<h4>Objective</h4>To define the prevalence and clinical phenotype of anti-cortactin autoantibodies in adult and juvenile myositis.<h4>Methods</h4>In this longitudinal cohort study, anti-cortactin autoantibody titers were assessed by enzyme-linked immunosorbent assay in 670 adult myositis patients and 343 juvenile myositis patients as well as in 202 adult healthy controls and 90 juvenile healthy controls. The prevalence of anti-cortactin autoantibodies was compared among groups. Clinical features of patients with and those without anti-cortactin autoantibodies were also compared.<h4>Results</h4>Anti-cortactin autoantibodies were more common in adult dermatomyositis (DM) patients (15%; P = 0.005), particularly those with coexisting anti-Mi-2 autoantibodies (24%; P = 0.03) or anti-NXP-2 autoa2022-01-01T00:00:00Z2022 Feb2026-05-05T03:25:18.938Z2025-04-05T09:05:56.996ZS-EPMC87920923431339410.1002/art.41931